Speakers

Anne E. Carpenter, Ph.D., Director, Imaging Platform, Broad Institute of Harvard and MIT

Neil Carragher, Ph.D., Principal Investigator, Drug Discovery, Institute of Genetics and Molecular Medicine, University of Edinburgh

Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging, Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology

Regis Doyonnas, Ph.D., Senior Principal Scientist, High-Content Screening and HTS-Flow Cytometry, Hit Discovery and Lead Profiling, Worldwide Research & Development, Pfizer

Marc Ferrer, Ph.D., Team Leader, Pre-Clinical Innovation, NCATS, NIH

Rebecca Green, Ph.D., Research Scientist, Ludwig Institute for Cancer Research

Lesley Mathews Griner, Ph.D., Investigator & Lab Head, Molecular Pharmacology/Oncology, Novartis Institutes for BioMedical Research

Peter Horvath, Ph.D., Group Leader, Synthetic and Systems Biology Unit, Hungarian Academia of Sciences; Finnish Distinguished Professor (FiDiPro) Fellow, Institute for Molecular Medicine Finland

Keith Houck, Ph.D., Research Scientist, National Center for Computational Toxicology, U.S. Environmental Protection Agency

Mark Hurle, Ph.D., Senior Scientific Investigator, Systematic Drug Repositioning, Computational Biology, GlaxoSmithKline

James Inglese , Ph.D., National Center for Advancing Translational Sciences, NIH

Michael Jackson, Ph.D., Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute

Tae-Wan Kim, Ph.D., Associate Professor, Pathology and Cell Biology, Columbia University Medical Center

Stefan Kustermann, Ph.D., Head, High Content Imaging, Pharmaceutical Sciences, Roche Pharma Research and Early Development, Roche Innovation Center Basel

Daniel V. LaBarbera, Ph.D., Assistant Professor, Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado

Annie Mak, Ph.D., Research Investigator, Assay Development and HTS, Genomics Institute of the Novartis Research Foundation

Robert F. Murphy, Ph.D., Ray and Stephanie Lane Professor of Computational Biology and Professor of Biological Sciences, Biomedical Engineering and Machine Learning; Director, Lane Center for Computational Biology, Carnegie Mellon University

Dana Nojima, Ph.D., Senior Scientist, Discovery Technology, Amgen

David Nolte, Ph.D., Professor, Physics, Purdue University; President, Animated Dynamics, Inc.

Michelle Palmer, Ph.D., Director, Discovery and Preclinical Research, Broad Institute

Christian N. Parker, Ph.D., Senior Investigator, Developmental and Molecular Pathways, Novartis AG

Michael Persson, Ph.D., Primary Exploratory Toxicologist, Exploratory Toxicology, H. Lundbeck A/S

Liang Schweizer, Ph.D., Director, Leads Discovery & Optimization, Bristol-Myers Squibb

Larry A. Sklar, Ph.D., Director, University of New Mexico Center for Molecular Discovery

Yangzhong Tang, Ph.D., Research Investigator, Sanofi

D. Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute; Allegheny Foundation Professor, Computational and Systems Biology, University of Pittsburgh

Fredrick Van Goor, Ph.D., Senior Research Fellow, Vertex Pharmaceuticals

Fabien Vincent, Ph.D., Associate Research Fellow, Assay Development and Pharmacology, Hit Discovery and Lead Profiling, Pfizer Global Research & Development

Andreas Vogt, Ph.D., Associate Professor, Computational and Systems Biology, University of Pittsburgh

Alan Waggoner, Ph.D., Professor, Biological Sciences; Director, Molecular Biosensor and Imaging Center, Carnegie Mellon University

Armin Wolf, Ph.D., Professor and Director, Preclinical Safety, Novartis Institutes for BioMedical Research

Stephen T.C. Wong, Ph.D., Chair and Professor, Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medical College

Wensheng Xie, Ph.D., Investigator, Target and Pathway Validation, GlaxoSmithKline

Wei Zheng, Ph.D., Group Leader, Preclinical Innovation, NCATS, NIH

Sannah Zoffmann, Ph.D., Phenotypic Drug Development and Target Identification, F. Hoffmann-La Roche